GreyBird Portfolio Companies: Ceres Nano

The Clinical Problem

Precision Medicine Diagnostics requires a test that has both high sensitivity and high specificity.  Unfortunately, biomarkers that are highly specific are often low in abundance – especially in the early stages of disease.

The Ceres Solution

The Ceres Nanotrap® technology, protected by 13 issued patents, increases the concentration of targeted biomarkers 10 to 1000 times. It not only captures, concentrates, and preserves the targeted biomarker, it allows detection in urine or saliva.

The Business Plan

Ceres Nanosciences is focused on the commercialization of the Nanotrap® particle technology for sample preparation. The Nanotrap particle technology improves diagnostic testing and life science research by capturing, concentrating, and preserving low abundance analytes from biological samples. With support from the Defense Advanced Research Projects Agency, the Bill and Melinda Gates Foundation, the Defense Threat Reduction Agency, the NIH, and the Commonwealth of Virginia, Ceres is focused on incorporating this technology into a range of innovative diagnostic products.

Latest News from Ceres Nano

Streck establishes partnership with Ceres Nanosciences to distribute COVID-19 wastewater surveillance solution


Ceres Nanosciences Establishes Nine Wastewater-based COVID-19 Surveillance Centers of Excellence Under NIH RADx Initiative


NIH Awards Ceres Nanosciences $8.2M for Wastewater-Based COVID-19 Surveillance


Ceres Nanosciences adding manufacturing facility, 50 jobs to improve COVID-19 tests – Washington Business Journal